Molecular wanderings through the DNA damage response and risk for ovarian cancer

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Bookman, Michael A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53; PROTEIN PHOSPHATASE MAGNESIUM DEPENDENT 1 DELTA; RAD51 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2C;

CANCER DIAGNOSIS; CANCER RISK; CHROMOSOME 17Q; CHROMOSOME LOSS; DNA DAMAGE; EDITORIAL; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR DIAGNOSTICS; MOLECULAR PATHOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; FEMALE; GENETICS; LEUKOCYTE; METABOLISM; MUTATION; NOTE; OVARY TUMOR;

FEMALE; HUMANS; LEUKOCYTES; MUTATION; OVARIAN NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES;

EID: 84892651347     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt350     Document Type: Editorial

References (5)

1. Akbari MR, Lepage P, Rosen B, et al. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. JNCI J Natl Cancer Inst (2014) 106 (1): djt323 doi:10.1093/jnci/djt323
2. Ruark E, Snape K, Humburg P, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406- 410.
3. Kleiblova P, Shaltiel IA, Benada J, et al. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol. 2013;201(4):511-521.
4. Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene. 2012;31(17):2175-2186.
5. Tan DS, Lambros MB, Rayter S, et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 2009;15(7):2269-2280.